{"id":43925,"date":"2022-05-16T11:02:11","date_gmt":"2022-05-16T09:02:11","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/proteros-expands-oncology-collaboration-and-license-agreement-with-astrazeneca\/"},"modified":"2022-05-16T11:02:11","modified_gmt":"2022-05-16T09:02:11","slug":"proteros-expands-oncology-collaboration-and-license-agreement-with-astrazeneca","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/proteros-expands-oncology-collaboration-and-license-agreement-with-astrazeneca\/","title":{"rendered":"Proteros Expands Oncology Collaboration and License Agreement with AstraZeneca"},"content":{"rendered":"
\n

\n— Under the expanded collaboration, Proteros will receive additional research funding, milestone payments plus royalties —\n<\/p>\n

MUNICH–(BUSINESS WIRE)–Proteros biostructures GmbH<\/a> (\u201cProteros\u201d), an expert in integrated structure-based drug discovery, announces today an expansion of its collaboration with AstraZeneca (LSE\/STO\/Nasdaq: AZN) focused on the discovery and development of novel epigenetic drugs. The new multi-year agreement builds on an ongoing collaboration with AstraZeneca announced<\/a> in June 2021, to include the development of small molecule inhibitors targeting a second cancer-associated epigenetic protein.\n<\/p>\n

<\/a><\/p>\n

\nUnder the terms of this new agreement, Proteros will receive research funding and will be eligible for success-based research, development, and commercial milestone payments of up to USD 75 million plus tiered royalties on annual net sales. The collaboration combines Proteros\u2019 expertise in the identification and characterization of inhibitors with novel binding mechanisms for technically challenging drug targets with AstraZeneca\u2019s leadership in the discovery and development of oncology medicines.\n<\/p>\n

\n\u201cThe expansion of our agreement with AstraZeneca with an additional drug discovery program reflects our successful ongoing collaboration to identify selective inhibitors for notoriously challenging disease targets,\u201d said Dr. Torsten Neuefeind, CEO of Proteros. \u201cThis agreement strengthens our collaboration with a global biopharmaceutical leader and we look forward to joining forces again to discover novel inhibitors with the potential to effectively treat cancer patients in the future.\u201d\n<\/p>\n

\nThe Proteros platform will ensure high selectivity to a specific target variant within and across multiple protein families through biochemical, biophysical and cellular assays supported by rapid turnaround in the structural determination of drug-target interactions by X-ray crystallography and cryo-Electron Microscopy technologies.\n<\/p>\n

\nAbout Proteros biostructures GmbH<\/b>\n<\/p>\n

\nProteros is a privately-held company with expertise in structure-based drug discovery powered by a cutting-edge discovery engine tailored to unlock even the most technically challenging disease-relevant targets. The company\u2019s scientific rigor can accelerate overall research timelines for clients by solving challenges at the initial drug discovery and development stages. Proteros supports many of the top 20 world\u2019s largest pharmaceutical companies and more than 250 pharmaceutical and biotech partners in the U.S., Europe and Japan.\n<\/p>\n

\nFor more information please visit www.proteros.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nFor Proteros<\/b>
Dr. Torsten Neuefeind
\n
Chief Executive Officer
\n
Phone: +49 89 700761-0
\n
Email: info@proteros.com<\/a>\n<\/p>\n

\nMedia Requests for Proteros<\/b>
Trophic Communications
\n
Jacob Verghese or Gretchen Schweitzer
\n
Phone: +49 89 2070 89831
\n
Email: proteros@trophic.eu<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

— Under the expanded collaboration, Proteros will receive additional research funding, milestone payments plus royalties — MUNICH–(BUSINESS WIRE)–Proteros biostructures GmbH (\u201cProteros\u201d), an expert in integrated structure-based drug discovery, announces today an expansion of its collaboration with AstraZeneca (LSE\/STO\/Nasdaq: AZN) focused on the discovery and development of novel epigenetic drugs. The new multi-year agreement builds on … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-43925","6":"format-standard","7":"category-industry"},"yoast_head":"\nProteros Expands Oncology Collaboration and License Agreement with AstraZeneca - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/proteros-expands-oncology-collaboration-and-license-agreement-with-astrazeneca\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Proteros Expands Oncology Collaboration and License Agreement with AstraZeneca - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"— Under the expanded collaboration, Proteros will receive additional research funding, milestone payments plus royalties — MUNICH–(BUSINESS WIRE)–Proteros biostructures GmbH (\u201cProteros\u201d), an expert in integrated structure-based drug discovery, announces today an expansion of its collaboration with AstraZeneca (LSE\/STO\/Nasdaq: AZN) focused on the discovery and development of novel epigenetic drugs. The new multi-year agreement builds on ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/proteros-expands-oncology-collaboration-and-license-agreement-with-astrazeneca\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-05-16T09:02:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220516005058\/en\/1454724\/21\/Proteros_logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/proteros-expands-oncology-collaboration-and-license-agreement-with-astrazeneca\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/proteros-expands-oncology-collaboration-and-license-agreement-with-astrazeneca\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Proteros Expands Oncology Collaboration and License Agreement with AstraZeneca\",\"datePublished\":\"2022-05-16T09:02:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/proteros-expands-oncology-collaboration-and-license-agreement-with-astrazeneca\\\/\"},\"wordCount\":386,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/proteros-expands-oncology-collaboration-and-license-agreement-with-astrazeneca\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220516005058\\\/en\\\/1454724\\\/21\\\/Proteros_logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/proteros-expands-oncology-collaboration-and-license-agreement-with-astrazeneca\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/proteros-expands-oncology-collaboration-and-license-agreement-with-astrazeneca\\\/\",\"name\":\"Proteros Expands Oncology Collaboration and License Agreement with AstraZeneca - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/proteros-expands-oncology-collaboration-and-license-agreement-with-astrazeneca\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/proteros-expands-oncology-collaboration-and-license-agreement-with-astrazeneca\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220516005058\\\/en\\\/1454724\\\/21\\\/Proteros_logo.jpg\",\"datePublished\":\"2022-05-16T09:02:11+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/proteros-expands-oncology-collaboration-and-license-agreement-with-astrazeneca\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/proteros-expands-oncology-collaboration-and-license-agreement-with-astrazeneca\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/proteros-expands-oncology-collaboration-and-license-agreement-with-astrazeneca\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220516005058\\\/en\\\/1454724\\\/21\\\/Proteros_logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220516005058\\\/en\\\/1454724\\\/21\\\/Proteros_logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/proteros-expands-oncology-collaboration-and-license-agreement-with-astrazeneca\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Proteros Expands Oncology Collaboration and License Agreement with AstraZeneca\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Proteros Expands Oncology Collaboration and License Agreement with AstraZeneca - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/proteros-expands-oncology-collaboration-and-license-agreement-with-astrazeneca\/","og_locale":"en_US","og_type":"article","og_title":"Proteros Expands Oncology Collaboration and License Agreement with AstraZeneca - Pharma Trend","og_description":"— Under the expanded collaboration, Proteros will receive additional research funding, milestone payments plus royalties — MUNICH–(BUSINESS WIRE)–Proteros biostructures GmbH (\u201cProteros\u201d), an expert in integrated structure-based drug discovery, announces today an expansion of its collaboration with AstraZeneca (LSE\/STO\/Nasdaq: AZN) focused on the discovery and development of novel epigenetic drugs. The new multi-year agreement builds on ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/proteros-expands-oncology-collaboration-and-license-agreement-with-astrazeneca\/","og_site_name":"Pharma Trend","article_published_time":"2022-05-16T09:02:11+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220516005058\/en\/1454724\/21\/Proteros_logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/proteros-expands-oncology-collaboration-and-license-agreement-with-astrazeneca\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/proteros-expands-oncology-collaboration-and-license-agreement-with-astrazeneca\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Proteros Expands Oncology Collaboration and License Agreement with AstraZeneca","datePublished":"2022-05-16T09:02:11+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/proteros-expands-oncology-collaboration-and-license-agreement-with-astrazeneca\/"},"wordCount":386,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/proteros-expands-oncology-collaboration-and-license-agreement-with-astrazeneca\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220516005058\/en\/1454724\/21\/Proteros_logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/proteros-expands-oncology-collaboration-and-license-agreement-with-astrazeneca\/","url":"https:\/\/pharma-trend.com\/en\/proteros-expands-oncology-collaboration-and-license-agreement-with-astrazeneca\/","name":"Proteros Expands Oncology Collaboration and License Agreement with AstraZeneca - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/proteros-expands-oncology-collaboration-and-license-agreement-with-astrazeneca\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/proteros-expands-oncology-collaboration-and-license-agreement-with-astrazeneca\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220516005058\/en\/1454724\/21\/Proteros_logo.jpg","datePublished":"2022-05-16T09:02:11+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/proteros-expands-oncology-collaboration-and-license-agreement-with-astrazeneca\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/proteros-expands-oncology-collaboration-and-license-agreement-with-astrazeneca\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/proteros-expands-oncology-collaboration-and-license-agreement-with-astrazeneca\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220516005058\/en\/1454724\/21\/Proteros_logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220516005058\/en\/1454724\/21\/Proteros_logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/proteros-expands-oncology-collaboration-and-license-agreement-with-astrazeneca\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Proteros Expands Oncology Collaboration and License Agreement with AstraZeneca"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/43925","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=43925"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/43925\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=43925"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=43925"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=43925"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}